LATEST COMPANY NEWS. - Free Online Library (2024)

Link/Page Citation

China News - the 2024 China Pharmaceutical Marketing Big Data Summit to discuss the development of the industry empowered by big data - 31/3/2024

For the Chinese language, see:

https://www.cq.chinanews.com.cn/fgs/2024/0331/16-6462.html

Hangzhou News - Aromatherapy apply to ailments - 31/3/2024

For the Chinese language, see:

https://ori.hangzhou.com.cn/ornews/content/2024-03/31/content_8709269.htm

Orential Daily - Only nearly half of the Chinese medicine practitioners in the country are registered. Zheng Jianqiang calls on doctors to seize the opportunity to register. - 31/3/2024

For the Chinese language, see:

https://www.orientaldaily.com.my/news/central/2024/03/31/641545

Chinese oncology therapeutic companies showed a 150% increase in the number of IPO deals from 2019 to 2020 compared to other therapy areas, as shown in Figure 1. RemeGen raised $514M for its IPO completed in November 2020, with the majority of its drug pipeline for Oncology. Jiangsu Hansoh Pharmaceutical Group remains on top with the largest IPO deal in China of $1B completed in June 2019, with its drug pipeline spanning across many of the top therapy areas. However, China still lags behind the US in number of IPOs completed from 2019 to October 2021, with the US having 5.5 times more completed IPO deals compared to China, according to GlobalData's Pharma Intelligence Center Deals Database.

In September 2021, the President of China Xi Jinping, announced plans for a new stock exchange in Beijing to provide financing for innovative small and medium-size companies. This would be similar to the Shanghai Stock Exchange Science and Technology Innovation Board (STAR) launched in July 2019, as a rival to the US Nasdaq, to encourage innovative companies to list before they have a marketed drug. However, the number of biotech companies with innovator drugs listed on the Nasdaq and New York stock exchanges is still higher than on China's Shanghai and Shenzhen exchanges.

The downturn in Chinese IPOs in 2021 was due to the Shanghai Stock Exchange remaining flat where the top companies on the SSE 50 and SSE 80 indices have been down. It remains to be seen if the number of Chinese bio/pharma companies going public may change for next year.

Source: Pharmaceutical Technology.

https://www.pharmaceutical-technology.com/comment/chinese-bio-pharma-oncology/

Leading Companies

Beijing Tongretang Co., Ltd. (SHA: 600085)

Tongrentang Group Basic Information.

China Beijing Tongrentang (Group) Co., Ltd. is a wholly state-owned company authorized by the Beijing Municipal Government to operate state-owned assets. Beijing Tongrentang was founded in 1669 and has a history of 350 years. It is a well-known old brand in the Chinese medicine industry.

In history, Tong Ren Tang once served the Qing dynasty royal medicine, after eight generations of emperors 188 years. After liberation, Tong Ren Tang actively responded to the government's call and first took the lead in achieving public-private partnerships in 1954. In July 1992, with the approval of the Beijing Municipal Government, Beijing Tongrentang Group Co., Ltd. was formally established and later restructured into a wholly state-owned Beijing Tongrentang (Group) Co., Ltd. In 1997, the group carried out a share reform and established a state-controlled Beijing Tongrentang Co., Ltd., which was listed on the Shanghai Stock Exchange. In 2000, Tongrentang Co., Ltd. "divided" some assets and established Beijing Tongrentang Technology Development Co., Ltd., which was listed in Hong Kong that year. In May 2013, Beijing TongrentangSinopharm Co., Ltd. was listed on the Hong Kong Growth Enterprise Market and became the third listed company under Tongrentang. In May 2018, it completed the transfer to the Main Board.

By the end of 2018, Tongrentang Group had more than 2,600 kinds of six major categories of products such as medicines and health foods, 36 production bases, 110 modern production lines, a national engineering center and post-doctoral research stations. The group system has a total of 2,227 retail terminals (including 149 overseas); 561 medical service terminals (including Chinese medicine hospitals and clinics) (including 80 overseas).

In recent years, Tongrentang has adhered to reform and innovation, adhered to the strategic goal of "making excellence, excellence, strength, and long-term", and formulated the development orientation of "building an internationally renowned and domestically leading health industry group with Chinese medicine as its core". Focusing on the main business, we will vigorously promote the construction of industrial bases, commercial networks and talent teams, technological innovation, and information network platforms. Tongrentang has formed seven secondary groups (including: stock group, science and technology development group, Sinopharm Group, health pharmaceutical group, commercial investment group, medicinal materials ginseng group, medical care group), two institutes (research institutes, education colleges) ), a modern, internationalized Chinese medicine group of several directly affiliated companies.

Tongrentang, while realizing the steady development of the economy, fully exerted the role of cultural carrier, especially the protection and inheritance of non-legacy culture has been widely recognized by all walks of life at home and abroad. Tongrentang has 10 non-legacy projects (including 3 at the national level). Under the strong support, help and guidance of governments at all levels, Tong Ren Tang actively contributes to the dissemination and promotion of Chinese medicine culture.

https://www.tongrentang.com/article/70.html

2021 Interim Report

19/8/2021

For the full release, see:

https://staticpacific.blob.core.windows.net/press-releases-attachments/1330379/HKEX-EPS_20210819_9900146_0.PDF

China National Pharmaceutical Group Co., Ltd. (Sinopharm)

About Us.

China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.

Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.

The past years witnessed Sinopharm's steady and sound development. From 2009to 2018, the CAGR of revenue and total assets reached 24.24% and 30.54% respectively. Sinopharm ranked 169th in Fortune Global 500 and the revenue of 2018 amounted to nearly 400 billion yuan..

Sinopharm has built a nationwide logistic and distributing network for drugs and medical devices and equipment, including 5logistic hubs, more than 40 provincial-level centers and over 240 municipal-level logistic sites. By establishing the smart medical service system, Sinopharmdelivers quality servicesto more than 230,000 corporate clients.

Sinopharm has an applied pharmaceutical research institute and an engineering design institute, both taking a leading position in China. Two Academicians of Chinese Academy of Engineering, 11 national R&D institutes, 44 provincial-level technology centers and over 5,000 scientists have made remarkable achievements.Sinopharm also chaired in setting over 530 national technical criteria, among which the EV71 vaccine, a first category new drug of China with Sinopharm holding complete independent intellectual property right, reduces the morbidity of hand-foot-and mouth disease among Chinese children. The R&D and launch of sIPV ensures the progress of the national immunization program for polio.

Sinopharm has built up manufacturing and medicinal materials sites for biological drugs, narcotic and psychotropic drugs, anti-infectious drugs, oncology drugs, cardio-vascular drugs and respiratory drugs. Some of the production lines have been approved by the US FDA and EU authorities, and prequalified by WHO.

As world's 6th largest vaccine manufacturer, Sinopharm is able to produce all the vaccines in the National Vaccination Program and is the supplier of over 80% vaccines used in the Expanded Program on Immunization in China.

Sinopharm leads in TCM sector by establishing an integrated TCM industry chain that covers planting, R&D, pieces for decoction, formulated instant granules, and preparations. It is able to produce over 900 medicines,owns 15 China Time-honored Brands and 4 National Intangible Cultural Heritage medicines.

Sinopharmhas fostered 30 highly recognized events represented by CMEF (China International Medical Equipment Fair), serving the entire chain and many subdivisions concerning healthcare. These exhibitions and conferences have become a platform for exchange and cooperation that advances the whole industry.

Sinopharm explored a new model of drugstores with extensive healthcare services. There are over 5,100 chain drugstores under the brands of Guoda, Jinxiang, Dadesheng and Tianyitang, providing convenientaccess for customers. Sinopharm forms a healthcare network consisting of regional healthcare groups in provinces of Henan, Hubei, Liaoning, and Heilongjiang. Sinopharm provides easier access to healthcare services for the people in dozens of our medical institutions with more than 10,000 beds in total.

Sinopharm broadens its international cooperation by founding 26 joint ventures with world-renowned pharmaceutical companies andtrading with more than 120 countries and regions, including60 Belt and Road countries.

The JE vaccine of which Sinopharm owns complete independent intellectual property right has been listed into the procurement catalog by the UN organizations to benefit the whole world.Sinopharm'sproduction sites in Vietnam and Malaysia, along withthe China-aided hospitals and mobile clinicsconstructed by Sinopharm in Myanmar and Cambodia,not only provide jobs for the local people, but also make greatcontributions to their well-beings.

As healthcare-centered financial services develop, an industry-and-finance model with Sinopharm features takes shape.

Guided by the core value of "all for health, health for all", Sinopharm shoulders the social responsibility of national medical and pharmaceutical reserve on a long-term basis with pride. In times of epidemics and disasters, it provides medicines, bio-products, traditional Chinese medicines, and medical devices promptly to the stricken areas not only at home, but also abroad as in Ecuador earthquake relief and in Myanmar influenza A/H1N1 prevention and control, contributing to ensure a sound public health condition for the people.

Sinopharm acts as the president enterprise in many influential associations such as China Pharmaceutical Industry Association, China National Narcotic Drugs Association, China Association of Pharmaceutical Commerce, etc., and plays its role in preventing diseases, safeguarding people's health, and advancing the whole industry.

http://www.sinopharm.com/en/1398.html

C & O Pharmaceutical Technology Holdings

CORPORATE PROFILE.

C & O Pharmaceutical Technology (Holdings) Limited ("C&O" or "We") was incorporated in 2003 and history of its foundation can trace back to 1997. C&O has been achieving fast development in the rapid growth of China pharmaceutical market throughout these years. In 2011, we joined as the member with shareholding of 71% and 29% held under Shionogi & Co., Ltd. ("Shionogi") and Sumitomo Corporation ("Sumitomo") (collectively referred to as "the Headquarter"), respectively. In the process of the "Headquarter Globalization", we are playing an important role in China among the huge market activities.

C&O is one of the few pharmaceutical enterprises in China integrating functions of the research and development, manufacture, and marketing and distribution, which aims to achieve as the "New Drug Market Enterprise".

Technology Research and Development.

C&O owns two research and development centers now locating at Nanjing Economic Technology Development Zone and National Shanghai Biomedical Technology Industry Base, which are operated under its subsidiary, Nanjing Changao Pharmaceutical Technology Co., Limited ("Nanjing R&D") and Shanghai Sun-sail Pharmaceutical Science & Technology Co., Limited ("Shanghai Sun-sail"), respectively.

Nanjing R&D was established in 1999, which is the key "High and New Technology Enterprise" recognized under the "National Torch Program" in China, is mainly engaged in drug research and development both in the preclinical and clinical stage.

Shanghai Sun-sail was established in 2004 with strong capabilities and strengths in the synthesis and screening of new compounds, which is mainly engaged in the research and development of innovation drug covering areas in anti-drug-resistant bacteria, anti-drug-resistant tuberculosis, anti-diabetes and anti-insomnia.

C&O cares a lot works on the research and development of innovation and the protection of intellectual property. We have developed the mid to long term strategic planning for the development of intellectual property and apply the same to enhance the core competitiveness of enterprise in order for speeding up our development. At present, some innovation drugs with independently developed intellectual property had entered the clinical stage and the technical knowhow was successfully transferred. On the other hand, a number of innovative compounds have become ready in application for the clinical stage.

Industrial Production.

C&O owns its factory now locating at Jiangbei New Area Intelligent Manufacturing Industrial Park, Nanjing, Jiangsu Province ("the Factory"), which is operated under its subsidiary, Nanjing Chang Ao Pharmaceutical Co., Limited ("Nanjing Chang Ao"). Nanjing Chang Ao has been specializing in the manufacture of a wide range of drug formulations including the freeze-dried powder injection, solid preparations and externally used medicine with the production approval for 81 products, mainly including Aobo Ping® (Rabeprazole Sodium for Injection), Firest® (Pantoprazole Sodium for Injection), Fush*tan® (Pantoprazole Sodium Enteric-coated Capsules), Ophen® (Clarithromycin Dispersible Tablets) and Antaen® (Diclofenac Sodium Sustained Release Capsules/Diclofenac Sodium Gel), etc. It is renowned in the society and also recognized as the "High and New Technology Enterprise" by the Jiangsu Provincial Government.

In order to maintain best quality of drug, C&O had decided in 2012 to construct the Factory equipping with fully upgraded facilities and those constructions were then completed in 2016. The Factory mainly comprises of the Freeze-dried Powder Workshop, Ordinary Solid Workshop and External Drug Workshop, as well as the supporting facilities, such as storage, quality inspection and office premises, etc. Construction for the Factory was awarded the thorough national GMP certification following its completion in 2016 and the facilities are then put into use and production. The new facilities provide annual production capacity with 20 million of freeze-dried powder injection, 360 million of tablets, 300 million of capsules and 7.5 million of ointment and gel preparations.

The Factory currently produce various types of drugs covering antibiotics, cardiovascular and cerebrovascular drugs, and digestive system drugs, etc., mainly in the formulation of freeze-dried powder injection, tablets, capsules, and ointment and gel preparations. Those productions are conducted under sound system of production quality management.

While we utilize capacity of the GMP certified production facilities, we always keep products quality first and stable products supply. Meanwhile, Nanjing Chang Ao owns a large number of patented and "High and New Technology" products which have won many awards from the Jiangsu Provincial Government.

Promotion and Distribution.

Shenzhen Liancheng Medicine Company Limited ("Shenzhen Liancheng") is the C&O distribution center, which holds two subsidiaries, Nanjing Xinaokang Pharmaceutical Limited ("Nanjing Xinaokang") and Sichuan Changao Medicine Company Limited ("Sichuan Changao").

Shenzhen Liancheng and its subsidiaries have passed the new national GSP certification and the achievement represents that they have attained an upper level in respect of the drug quality risk control, cold chain management, computing software management system and people management.

The head office of Shenzhen Liancheng locates at Shenzhen Special Economic Zones, Guangdong Province. It is engaged in the distribution of prescription drug and OTC drug, mainly including the own branded product, Aobo Ping® (Rabeprazole Sodium for Injection) and the high quality imported product, Amoxycillin (Amoxicillin Capsules). As a large commercial distribution enterprise in the pharmaceutical industry, Shenzhen Liancheng place its focus on the business channels and distribution networks covering distributors, hospitals, clinics and pharmacies.

Having been experienced and contributed from the process of sales in the past 20 years, C&O has successfully built up the well known brand of antibiotic, "Amoxycillin", which is our exclusive distribution of imported product. In the 7 consecutive years from 2011 to 2017, it was on the list of "Health China - China Medicine Brand List". In additions, we launched the first "Rabeprazole Sodium for Injection - Aobo Ping®", in China in April 2014, which is our independently developed product.

On the launch of Aobo Ping®, it is the "Key Breakthrough" in field of the domestic digestive system drug over China and the market share of Aobo Ping® is now growing up.

C&O Pharmaceutical Technology (Holdings) Limited ("C&O" or "We") was incorporated in 2003 and history of its foundation can trace back to 1997. C&O has been achieving fast development in the rapid growth of China pharmaceutical market throughout these years. In 2011, we joined as the member with shareholding of 71% and 29% held under Shionogi & Co., Ltd. ("Shionogi") and Sumitomo Corporation ("Sumitomo") (collectively referred to as "the Headquarter"), respectively. In the process of the "Headquarter Globalization", we are playing an important role in China among the huge market activities.

http://english.changao.com/profile.html

http://english.changao.com/

Harbin Pharmaceutical Group Co., Ltd. (SHA: 600664)

Harbin Pharmaceutical Group Co., Ltd. (HPGC) is a state-controlled Sino-foreign equity joint venture. It is composed of domestically famous pharmaceutical companies like HPGC General Factory, HPGC Sanjing, HPGC Sixth Factory, HPGC Chinese Medicine, HPGC Bioengineering and HPGC Vaccine, and commercial circulation companies like HPGC Medicine, HPGC Sales and HPGC Marketing. HPGC has two listed companies, HPGC Holding and HPGC Sanjing. HPGC owns 45.06% equity stake in HPGC Holding, and HPGC Holding owns 74.82% equity stake in HPGC Sanjing. HPGC has more than 20,000 employees, and total assets of 18.5 billion RMB.

HPGC is integrated with pharmaceutical manufacture, trade and R&D. We have seven main business segments, which are antibiotics, small-molecular drug preparations, OTC and healthcare products, modern Chinese medicines, biopharmaceuticals, animal vaccines and medicine circulations. We produce more than 20 dosage forms and over 1000 drugs. The annual production capacity is 15 thousand tons of API and intermediates, 2 billion vials of small-molecule drug for injection, 100 million vials of Chinese medicine for injection, 180 million vials of solution injections, 11 billion tablets, 14 billion capsules, 2.2 billion vials of oral solutions and 30 billion doses of animal vaccines.

HPGC products are sold throughout China and more than fifty other countries. The market shares of cephalosporin APIs and preparations, healthcare product series of calcium supplements, and Chinese medicines for injection consistently rank first in the country. Part of our products has reached European, Asian, African, and Middle and North American markets. The annual foreign exchange earning is more than 100 million dollars. More than 100 products exceed revenue of 10 million RMB, over 30 of which exceed 100 million RMB.

HPGC has 5 Chinese Famous Trademarks, which are Hayao, Sanjing, Gaizhonggai, Hutong and Shiyitang. Hayao is one of the most valuable pharmaceutical brands in China and its brand value is evaluated to be worth 18.4 billion RMB. The operating profit and the main business revenue of HPGC have been in the front seats among Chinese Top 100 Pharmaceutical Companies for seven consecutive years since 2005.

In addition to establishing the strong brands, HPGC has put the rich resources accumulated by the aid of the famous brands into technology innovation. HPGC has been setting up the new R&D location - HPGC Pharmaceutical Academy since 2011. The R&D institute has full range of collaborations with domestic and international experts from prestigious universities and research institutes. Six research centers are established, which are research centers of small-molecule drugs, bioengineering drugs, drug preparations, modern Chinese medicines, OTC and healthcare products and animal vaccines. We have several innovative R&D platforms in the institute, such as technology platform of extended, controlled and immediate release, technology platform of fat emulsions, liposomes and lipid microspheres, and technology platform of biopharmaceutical PEGylation. With those platforms, we focus to develop our strength core technologies and products. We currently have over 140 new products. The penicillin and cephalosporin C fermentation technologies are in the world-advanced level. The constantly improved independent R&D system and the growing research team, along with the strong brands constitute the company's pair of wings.HPGC has received honors and awards including "Winner of Chinese Top 100 Pharmaceutical Companies","China's Most Respected Enterprise", "Champion of the Global Top 100 Chinese Companies", "China's Innovative Company with the Most Growth Potential", "Harbin Top 50 Taxpayers of Industry Companies", "the Top 10 Most Influential Pharmaceutical Enterprise Award", and "Key High-Tech Enterprise of National Torch Plan". They have brought wide attention and praise of the society to HPGC.

For year 2012, the gross industrial output of HPGC is 10.2 billion RMB, with revenue of 18 .0 billion RMB and profit of 885 million RMB.

Standing on the new start point that bears hope and vitality, HPGC will take practical actions to achieve leapfrog development under the new strategy of "Take a second pioneering journey through transformation and upgrade". We endeavor to join the Global 500 and become a world-class company with international competitiveness.

http://en.hayao.com/about/about1.html

North China Pharmaceutical Co., Ltd. (SHA: 600812)

North China Pharmaceutical Company Ltd. manufactures and markets pharmaceuticals. The Company produces antibiotic medicines, preparations, vitamins, immunomodulators, and other pharmaceutical products. North China Pharmaceutical markets its products worldwide.

https://www.bloomberg.com/quote/600812:CH

http://www.ncpc.cn/##

Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276)

Company Profile

Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Hengrui was established in 1970 and listed in Shanghai Stock Exchange in 2000. The company ranks top 30 worldwide by a market capitalization of about 50 billion USD, and is home to more than 24,700 employees worldwide. Hengrui not only stands out as a front-runner in cancer drugs, contrast agents, cancer drugs, and surgical medicines, but is also a lead member of the National Anti-Tumor Medicine Technology Innovation Industry-Education-Research Alliance. Hengrui owns a National Targeted Drug Engineering Technology Research Center, and a post-doctoral research station. In May 2018, Hengrui Medicine was listed in Forbes's top 100 world's most innovative companies and ranked the 64th, where only 7 companies from China were on the list. Further information is available at www.hrs.com.cn/hren

In the past decade, Hengrui maintained a CAGR of 23% in revenue, which exceeded 2 billion USD in 2017. A proportional growth in net profit was achieved and exceeded 470 million USD in 2017. Around 10% of the revenue is spent in R&D each year which reflects the dedication and competitiveness of Hengrui in innovation. As of Q3 2018, 1.81 billion USD in revenue and 321 million USD in tax was achieved.

Hengrui owns 10 R&D centers globally, where over 3,000 research staffs work on hundreds of therapeutic candidates, many of which have the potential of being the first-in-class or best-in-class. Hengrui is currently running more than 120 clinical trials worldwide. In recent years, Hengrui actively involved in 29 National Science and Technology Major Projects. With 4 innovative drugs (imrecoxib, apatinib, mecapegfilgrastim, and pyrotinib) launched in China, 1 product under NDA review, 30+ drug candidates in clinical development worldwide, and 50+ in pre-clinical stage, Hengrui is strengthening its leadership in oncology while diversifying its portfolio covering diabetes, pain management, autoimmune, CV/metabolics, and infectious diseases. Hengrui owns global patents for most of the products. 622 patent applications have been filed in China, 136 patents have been granted in China, and 221 patents have been granted in Europe, US, Japan, and other countries. Moreover, 2 Second Class National Science and Technology Progress Awards, and 1 Gold Award for Chinese Patent were granted to Hengrui.

Hengrui fully owns 8 manufacturing facilities for small and large molecules as well as medical devices. All facilities are approved and audited by NMPA, most also approved by US FDA, EDQM, TGA, and PMDA.

Hengrui's 14,000+ in-house sales & marketing force is able to reach out to 15,000+ hospitals in China, covering almost all the major hospitals and medical centers. Their extraordinary market execution capability extends from innovative drugs to less-differentiated products.

In 2018, Hengrui announced 2 out-licensing collaborations with Arcutis and TG Therapeutics, respectively, totaling up to 573 million USD in potential milestone payment to Hengrui. Hengrui also has a growing number of active research partnerships with world-renowned institutes.

Embracing the spirit of "Honesty and Trustworthiness, Quality First" as a business principle, Hengrui leads the Chinese markets for anti-cancer drugs, surgical anesthetics, specialized infusions, and contrast agents. To date, Hengrui has 10+ products approved in Europe, US, and Japan, covering injectables, oral formulations, and inhalational anesthetics, and has achieved remarkable sales in those markets. Pursuing the concept of "Excelling in Science, Enhancing Life", Hengrui sees its future as a Chinese multi-national pharmaceutical corporation, and continuously strives for innovation, progress, and achievement of new breakthrough in the healthcare industry.

https://www.hrs.com.cn/hren/About_hr_company.html

Livzon Pharmaceutical Group (SHE: 000513)

Livzon Pharmaceutical Group Inc. is a comprehensive pharmaceutical enterprise integrating research & development (R&D), production and marketing of medical and pharmaceutical products. It was founded with a registered capital of RMB 719 million in January 1985. By 2018, the total assets of the company were over RMB 17 billion, and the annual turnover was RMB 8.86 billion with more than RMB 1 billion net profit attributable to the shareholders of the Company. The Livzon Pharmaceutical Group has invested approximately RMB 687 million in R&D. In 1993, the stock of the Livzon Pharmaceutical Group was listed on the A-share, and subsequently the B-share market. In 2014, Livzon Pharmaceutical Group stock was successfully transferred from B-share to H-share, becoming one of the few pharmaceutical companies in China to be listed on both the A and H share market.

The Livzon Pharmaceutical Group has complete, modern industrial chains and product groups, manufactures chemical drugs, Chinese patent medicines, active pharmaceutical ingredients, microsphere and diagnostic reagents. The products in production and/or on sale including antibiotics and anti-tumor medications, traditional Chinese medicines, immunotherapy, and drugs pertaining to the fields of gastrointestinal, cardio-cerebral-vascular, and reproductive endocrine medicine. Among them the traditional Chinese medicine infusion ShenQiFuZheng injection and the company's primary drug Ilaprazole, the 2 drugs have successively won the First Prize of Scientific & Technological Progress Award in Guangdong. The related research on Ilaprazole and ShenQiFuZheng injection also won the Second Prize of the National Scientific & Technological Progress Award in succession.

https://en.livzon.com.cn/intro/2.html

2021 Third Quarter Report

25/10/2021

For the full release, see:

https://www.livzon.com.cn/public/html/pdfjs/viewer/viewernew.html?file=https://v4.cecdn.yun300.cn/site_1809140982/c_01513ann-20211025(20211025_1935)_ess1635165812625.pdf

North China Pharmaceutical Co., Ltd. (SHA: 600812)

https://www.bloomberg.com/quote/600812:CH

http://www.ncpc.cn/##

Northeast Pharmaceutical Group Co., Ltd (SHE: 000597)

Northeast Pharmaceutical Group Co., Ltd ("Northeast Pharm" for short), established in 1946, is a large-scale comprehensive pharmaceutical enterprise in China. Northeast Pharm is dedicated to the establishment of the whole industrial chain from R&D, production, medical commerce to medical engineering service. With the development for more than half of a century, Northeast Pharm has 352 national registration approval number, 12 series, over 400 raw materials and finished products. Manufacturing capacity is more than 13 billion units annually. Sales network covers more than 100 countries and areas in the world.

Creation is the source of vitality. We challenge the unknown and impossibility. Northeast Pharm has established a series of high-end science and technology platforms encompassing national technology center, medical industry research institute, designing institute, new drug incubation center, quality inspection center, post-doctoral scientific research station. Northeast Pharm has top-end experts and management personnel who enjoy great popularity in several fields, such as gynecology, andrology, intestine, cardiovascular, anti-AIDS, Narcotic psychotropic and anti-infection medicines.

Northeast Pharm insists on developing high quality chemical medicine and biological medicine using the best quality raw materials and the most advanced technology. All the products meet the latest standards of Chinese Pharmacopoeia, European Pharmacopoeia and United States Pharmacopeia. Following the principle of "Everything for your health", Northeast Pharm is dedicating to continuous technology innovation and providing high quality products and professional services to our customers and partners in the pharmaceutical and nutritional business.

https://www.nepharm-en.com/about-us

Shanghai Pharmaceuticals Holding Co., Ltd. (SHA: 601607, HK: 2607)

Shanghai Pharmaceuticals Holding Co. Ltd. ("SPH") is a vertically-integrated and diversified pharmaceutical group. The company has dual listings on the stock exchanges in Shanghai (601607) and Hong Kong (02067) respectively. The company provides leading healthcare services in: Research & Development, Manufacturing, Distribution and Retail.

In 2018, SPH reported revenues of US$23.6bn, making the company one of the country's major forces in the industry. SPH is one of the few listed pharmaceutical companies with a leading position in both manufacturing and distribution in China. It is included in the constituent stocks of both the SSE 180 and CSI 300 indices, and also selected into the Hang Seng Composite Index and MSCI.

http://english.sphchina.com/about_us/sph_overview.html

Shanghai Pharmaceuticals Group Co., Ltd. 2021 Annual Report

29/3/2022

For the full release, see:

https://www.sphchina.com/attached/files/601607_2021.pdf

Shandong Xinhua Pharmaceutical Co., Ltd. (HK: 719)

Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular system as well as finished dosage forms and pharmaceutical intermediates. With implementing the global market development strategy and adopting the international advanced standards in quality management, Shandong Xinhua has been granted the certifications of GMP, ISO9001, ISO14001, ISO 10012, and ISO22000. The main products of Shandong Xinhua have been granted the COS Certificate from EDQM and passed the site inspection from USA FDA. By taking the advantages of its solid scientific research strength, well-established quality system, high market reputation as well as being a listing company of H shares and A shares with sound capital structure and product portfolio. "XINHUA" brand was honored with the title of "Chinese Famous Brand" in China. With the high commitment to the product quality and development of the international markets, the Company has established the strategic partnership with dozens of MNCs, the products of the Company has been distributed to more than 60 countries and regions.

http://www.xhzy.com/html/english/default.aspx

2021 Annual Results Announcement

30/3/2022

For the full release, see:

http://xhzy.com/uploads/soft/20220330/1648641290.pdf

Shenzhen 999 Enterprise Group Co., Ltd.

Founded in December 1991, Sanjiu Enterprise Group, a state-owned enterprise directly supervised by the Stat Department, is one of the biggest herbal product manufacturers in China. Throughout 14 years' painstaking efforts, Sanjiu has developed into a national-famed integrated enterprise group, which presently is the controlling shareholder of companies (SANJIU MEDICAL & PHARMACEUTIAL Co., Ltd. ) and other 20 GMP standard pharmaceutical companies, many of which have been granted the TGA certificate of the Commonwealth of Nations. Featured by the core business domain of health industry and with the capability of manufacturing over 1, 000 sorts of herbal and chemical medicines in wide varieties of preparations, such as capsule, granule, oral liquid, injections powders, etc.Sanjiu made a turnover of RMB 8.6 billion yuan in 2004. And the 999 trademark has become a world famous health product brand, whose intangible assets has reached RMB 8.3 billion yuan.

Shenzhen 999 Chinese Medicine Investment & Development Co., Ltd., as a wholly owned key subsidiary company of Sanjiu Enterprise Group, is fully authorized to be in charge of Sanjiu's international health product market. It is responsible for the investment and management of the overseas subsidiary companies and (Traditional Chinese Medicine) clinics and supplies technological support for all the overseas agencies of the 999 health product. So far, we have set up our subsidiary companies in Hong Kong, Malaysia and Canada, and many clinics, with the products spread over the market of North America, Europe, Japan, Middle East and Southeast Asia. We are featured by Chinese Patent medicines, Health Food, Single Herbal Extracts, botanical extracts, injections and decocting machine. Many famous products such as 999 Weitai, 999 Ganmaoling, ZhuangGu Guan Jie Wan pills, Zheng Tan Wan pills, 999 Pi Yan Ping Ointment have been registered in many different counties. Besides, the chemical, biological medicines and raw materials presented by Sanjiu also provide the consumers more choices for medical treatment. Furthermore, based on our advantages of technologies and manufacturing scales, we are now supplying first-class OEM services to meet the demand of different markets from all over the world.

http://999sanjiu.en.made-in-china.com/

Sinopharm (China National Pharmaceuticals Group Co Ltd) (HKSE: 01099)

About Us.

As healthcare-centered financial services develop, an industry-and-finance model with Sinopharm features takes shape.

http://www.sinopharm.com/en/1398.html

Sinopharm Group Co., Ltd (HK: 1099)

Sinopharm Group Co. Ltd. (the "Company" or "Sinopharm Group", together with its subsidiaries referred to as the "Group"), which was established in January 2003 and listed on The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") (stock code: 01099. HK) in September 2009, is a core subsidiary of China National Pharmaceutical Group Corporation ("CNPGC") and the largest wholesaler and retailer of pharmaceutical and healthcare products and a leading supply-chain service provider in the PRC.

The Group is mainly engaged in pharmaceutical distribution business. Leveraging on its nationwide distribution and delivery network, the Group provides comprehensive distribution, logistics and other value-added services to domestic and foreign manufacturer and suppliers of pharmaceutical products, medical equipment and supplies and other healthcare products, and also to downstream customers including hospitals, other distributors, retail drug stores and primary health services institutions.

Meanwhile, the Group manages its network of retail drug stores chain in major cities of China via direct operations and franchises to sell pharmaceutical and healthcare products to end-customers. It has become a leader in China's pharmaceutical retail industry.

Besides, the Group is also engaged in the production and sale of pharmaceutical products, chemical reagents and laboratory supplies, and actively engaged in the innovation of pharmaceutical, medical services, finance leasing and other health-related industries, to explore the synergistic development of its diversified businesses.

Taking advantage of its superior economies of scale, customer resources, network platforms and brand position, the Group will fully leverage on China's pharmaceutical and healthcare market, which shows steady and healthy growth, and capture opportunities arising from healthcare reform to further consolidate and enhance its market leadership, actively striving to become a pharmaceutical and healthcare service provider with international competitiveness.

http://ir.sinopharmgroup.com.cn/html/about.php

Sinopharm Group Announces 2019 Interim Results Continuous Improvement in Market Share Maintaining Steady Business Growth

26/8/2019

Financial Highlights.

Revenue amounted to RMB201,665.14 million, representing an increase of 23.36% as compared with the corresponding period of last year;

Net profit amounted to RMB4,968.22 million, representing an increase of 13.08% as compared with the corresponding period of last year;

Profit attributable to owners of the parent amounted to RMB2,975.18 million, representing an increase of 6.33% as compared with the corresponding period of last year;

Basic earnings per share of the Company amounted to RMB1.00, representing an increase of 6.38% as compared with the corresponding period of last year.

Sinopharm Group Co. Ltd. ("Sinopharm" or the "Company", Stock Code: 1099.HK), the biggest wholesaler and retailer of pharmaceutical and healthcare products, as well as a leading supply chain service vendor in China, is pleased to announce the unaudited interim results of the Company and its subsidiaries (the "Group") for the six months ended 30 June 2019 (the "Reporting Period").

During the Reporting Period, the Group recorded revenue of RMB201,665.14 million, representing an increase of 23.36% as compared with the corresponding period of last year. The Group recorded a net profit of RMB4,968.22 million, representing an increase of 13.08% as compared with the corresponding period of last year; profit attributable to owners of the parent amounted to RMB2,975.18 million, representing an increase of 6.33% as compared with the corresponding period of last year. Basic earnings per share of the Company amounted to RMB1.00, representing an increase of 6.38% as compared with the corresponding period of last year.

With in-depth implementation of policies such as "two-invoice system", "zero mark-up", GPO policy in "4+7" pilot cities, the growth rate of the pharmaceutical distribution industry recorded a lower year-on-year growth but still continued to outperform the macroeconomic growth. The industry regulation has strengthened, the transformation and upgrade of the pharmaceutical distribution and retail industries have continued,2 the concentration ratio of the industry has further increased through merger and acquisition as well as integration undergone by enterprises, highlighting advantages in scale and branding. The environment of the pharmaceutical reform hastened the survival of the fittest in the distribution industry, the rise of leading enterprises such as Sinopharm would accelerate based on their own advantages in this round of transformation.

Solid leading position in the distribution business and significant increase in market share.

In the pharmaceutical distribution segment, the Group seized the historic opportunity of medical insurance reform, continued to optimize business and customer structure, made adjustment to product structures, constantly improved the leading national distribution network. Leveraging on an integrated pharmaceutical supply chain and an advanced supply chain management model, the Group continued its endeavors to promote integrated operation, plan for logistics network resources, speed up establishment and optimization of the logistics system and improved efficiency of the internal supply chain. During the Reporting Period, the pharmaceutical distribution business of the Group achieved a revenue of RMB164,700.64 million, representing an increase of 22.22% on a year-on-year basis. The Group continued to optimize its business layout, select suitable targets for integration, carry out acquisitions in areas with relatively weak business network, and strengthen control over core areas. In the first half of 2019, the Group successfully acquired100% equity interest in Anhui Pharmaceutical (Group) Co., Ltd. (å®å¾½çé«è¥ï¼éåï¼è¡ä»½æéå¬å¸), which effectively promoted the penetration of the business network to lower-tier market in Anhui province, and further improved the Group's business share and service capability in this region.

Ongoing rapid growth of retail business and fast development in professional pharmacies

Under the guidance of the "synergetic whole-retail" pharmaceutical business mode, the Group vigorously developed the retail business. On the one hand, traditional pharmacies of the Group constantly improved their own abilities in operation and management, accelerated network coverage, advanced creation of retail brands, optimized commodity structure, and increased the service standard for end consumers. On the other hand, the Group grasped the development trends of separation of medical services and pharmaceutical sales, prescription outflows, diversification of pharmaceutical terminal sales, and also actively explored the development of professional pharmacies. During the Reporting Period, the Group's retail business continued to achieve relatively rapid growth. Sales revenue reached RMB8,841.93 million, representing an increase of 24.51% over the corresponding period of last year. As at the end of the Reporting Period, Sinopharm Holding Guoda Drugstore Co., Ltd. ("Guoda Drugstore"), a subsidiary of the Company, has set up pharmacies covering 19 provinces, municipalities and autonomous regions across the country. The number of retail pharmacies was 4,593. The scale continued to lead the industry. The Group has 1,009 professional pharmacies as at 30 June 2019 with network covering 30 provinces, municipalities and autonomous regions across the country.

Rapid growth of medical device business.

The Group proactively seized golden opportunities arising in rapid development of the3 medical device industry, and vigorously developed the medical device distribution business. In the first half of 2019, the medical device business of the Group achieved rapid growth, with sales revenue reached RMB29,024.79 million, representing an increase of 35.96% over the corresponding period of last year, hence bringing significant contribution to both revenue and profit of the Group. In the meantime, the Group reinforced the expansion of new products and the development of new businesses, including the device IVD business, the SPD project and other medical innovation services, speeded up horizontal expansion of business segments, enlarged its regional coverage, further underpinning the Group's leading position in the medical device industry in the PRC.

Improving support capability of the headquarter, strict risk control and strengthened management and control.

The Group established the global procurement and supply chain service centre as the national centralized business platform for integration of national resources, centralization and standardization of traditional service capabilities and standard as to build intelligent supply chain. Meanwhile, relied on its industry leadership and strong corporate brand, the Group enhanced the interaction between the domestic industry and the global pharmaceutical industry, utilized the state-of-the-art technology, explored innovative services and products, continued to promote a "full track & trace" vaccine tracking system, thereby further increasing business advantages of the Group. In addition, the Group comprehensively conducted risk investigation and identification, improved the Group's creditability and accounts receivable management mechanism, controlled operational and compliance risks, reinforced management and business integration of acquirees and ensured high quality development through a series of measures.

Looking forward, the Group thinks that China's pharmaceutical industry has dived into the key stage of reform, facing new challenges and development opportunities. The Group will embrace the industrial trend of expedited transformation and structural adjustment, further optimize the Group's principal business, explore its core competitive advantages, diversify its business layout and explore new business mode, in order to consolidate the Group's status in the industry and ensure high quality development of the business through onging stable endogenous growth and strategic external expansion. As the largest and most powerful pharmaceutical distributor and retailer in China, Sinopharm will continue to consolidate leading position in distribution business and continuously increase market share, promote rapid growth of retail business and implement wholesale-retail pharmaceutical business synergetic development strategy, vigorously develop medical devices business and promote integration of devices business, and optimize operation management capabilities and enhance management and control services so that to further strengthen the accounts receivable management and inventory management. Under the guidance of the new strategy, we will strive to ensure sustainable high-quality development of the enterprise and build the Group into a global distinguished medical and healthcare service provider."

http://ir.sinopharmgroup.com.cn/html/news_detail.php?id=492972

Sinovac Biotech (NASDAQ: SVA)

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III trial. The company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mongolia, Nepal, the Philippines and Mexico, and was recently granted a license to commercialize its hepatitis A vaccine in Chile.

http://www.sinovac.com/?optionid=749

Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F

24/4/2021

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020.

Fourth Quarter and Full Year 2020 Financial Summary

Sales for the fourth quarter of 2020 were $327.5 million, an increase from $81.1 million in the prior year period.

Sales in 2020 were $510.6 million, an increase from $246.1 million in the prior year.

Operating income for the fourth quarter increased by 583.7% from the prior year period due to higher sales.

Operating income in 2020 increased by 214.5% from the prior year period due to higher sales.

The Company posted $107.3 million of net income attributable to common shareholders, or $1.09 per basic and $0.96 per diluted share, in the fourth quarter of 2020, compared to net income attributable to common shareholders of $21.7 million, or $0.22 per basic and $0.20 per diluted share, in the prior year period.

The Company posted $104.4 million of net income attributable to common shareholders, or $1.06 per basic and $0.97 per diluted share, in 2020, compared to net income attributable to common shareholders of $39.8 million, or $0.42 per basic and $0.41 per diluted share, in the prior year.

Mr. Weidong Yin, Chairman, President, and CEO of Sinovac, commented, "Sinovac experienced an exceptionally strong year in 2020. Despite the unprecedented COVID-19 pandemic, we are pleased with our record financial performance both for the fourth quarter and full fiscal year. We moved quickly to develop an inactivated COVID-19 vaccine, also known as CoronaVac, within a year's time and without having to sacrifice product quality."

"We have built production facilities with an annual production capacity of 2 billion doses. At this time, over 200 million doses of our COVID-19 vaccine have been delivered to different countries to support vaccine rollout, and millions of people around the globe have been administered our vaccine. We always strive to achieve low incident rates when developing vaccines, and we are happy to see CoronaVac's strong performance in the largest real world study in Chile, providing solid, real-life evidence that our vaccine helps to reduce hospitalized cases, ICU admissions, and fatal cases. Our overarching goal is to deliver a safe, effective, and accessible vaccine to the world."

Mr. Yin added, "As we worked to develop our COVID-19 vaccine, Sinovac also achieved good development progress with its other vaccine products as well. Two of our products, QIV and PPV-23, were granted market authorization in China in 2020, and our existing business segments continued to grow, despite a reduction in vaccination activities in the first half of the year due to the COVID-19 outbreak and lockdown policy."

Pipeline Development

COVID-19 Vaccine - The Company initiated the development of an inactivated vaccine against COVID-19 (named CoronaVac) on January 28, 2020. The phase I and II human studies on healthy adults aged 18 to 59 and elderly adults aged 60 and above were conducted in China and enrolled 144 participants in the phase I trial and 600 participants in the phase II trial, with 743 participants receiving at least one dose of investigational product. Results from the randomized, double-blind, placebo-controlled phase I/II clinical trial on safety, tolerability and immunogenicity of CoronaVac were published in The Lancet Infectious Diseases on November 17, 2020.

Since September 2020, the Company made rolling submission to China's National Medical Products Administration (NMPA), which carried out rolling reviews when the submissions were made. NMPA granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac in individuals aged 18 and above on February 5, 2021. As of March 31, 2021, CoronaVac has been granted either emergency approval or conditional marketing authorization by over 30 countries or regions.

Sinovac completed its phase I/II trial on pediatric populations aged 3 to 17 years old. 28 days after second dose, both the middle-dose and low-dose were well tolerated, and the seroconversaion rates were 96.77% and 100%, respectively. The pre-print of the publication named Safety, Tolerability and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Randomised, Double-Blind, and Placebo-Controlled, Phase 1/2 Clinical Trial is available at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3820545.

Sabin Inactivated Polio vaccine (sIPV) - The Company submitted an application to NMPA for the product license of sIPV in January 2019. The Company expects the license to be issued in mid-2021.

Unaudited Financial Results for the Fourth Quarter of 2020

Sales for the fourth quarter of 2020 were $327.5 million, an increase from $81.1 million in the prior year period. The increase was due to higher sales of the Company's influenza products, including the newly launched QIV, and sales of CoronaVac.

Gross profit in the fourth quarter of 2020 was $283.9 million, an increase from $68.9 million in the prior year period. Gross margin was 86.7%, compared to 84.9% in the prior year period. The increase of gross margin was due to a change in sales mix in 2020.

Selling, general and administrative expenses in the fourth quarter of 2020 were $83.1 million, compared to $33.3 million in the prior year period. The increase was mainly due to higher sales and increased marketing dedicated to revenue growth.

R&D expenses in the fourth quarter of 2020 were $2.7 million in 2020, compared to $7.8 million in the prior year period.

Net income in the fourth quarter of 2020 was $172.7 million, compared to $32.8 million in the prior year period, due to an increase in sales.

Net income attributable to common shareholders was $107.3 million, or $1.09 per basic and $0.96 per diluted share, in the fourth quarter of 2020, compared to $21.7 million, or $0.22 per basic and $0.20 per diluted share, in the prior year period.

As the Company announced on February 22, 2019, the Company's board of directors determined that certain shareholders became "Acquiring Persons," as defined in the Company's Rights Agreement ("Rights Agreement"), and a "Trigger Event" occurred under the Rights Agreement. As a result, the Company issued new common and preferred shares of Sinovac. Without the effect of implementing the Rights Agreement and the newly-issued common and preferred shares, basic and diluted earnings per share for the fourth quarter of 2020 would be $1.53 and $1.27, respectively.

Non-GAAP adjusted EBITDA was $198.9 million in the fourth quarter of 2020, compared to $30.8 million in the prior year period. Non-GAAP net income was $175.3 million in the fourth quarter of 2020, compared to $34.0 million in the prior year period. Non-GAAP diluted earnings per share in the fourth quarter of 2020 was $1.02, compared to earnings of $0.21 per share in the prior year period. Non-GAAP diluted earnings per share in the fourth quarter of 2020, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $1.36. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement.

The Company's fourth quarter 2020 financial statements are prepared and presented in accordance with U.S. GAAP. However, they have not been audited or reviewed by the Company's independent registered accounting firm.

Financial Results for the Twelve Months Ended December 31, 2020

Sales in 2020 were $510.6 million, an increase from $246.1 million in the prior year. The increase was due to higher sales of the Company's influenza products, including the newly launched QIV, and sales of CoronaVac.

Gross profit in 2020 was $443.4 million, compared to gross profit of $213.6 million in the prior year. Gross margin was 86.8%, which is the same compared to the prior year.

Selling, general and administrative expenses in 2020 were $176.5 million, compared to $121.5 million in the prior year. The increase was mainly due to higher sales and increased marketing dedicated to revenue growth.

R&D expenses in 2020 were $48.8 million, compared to $24.3 million in the prior year. The Company continued to invest in the advancement of pipeline vaccines, including sIPV and COVID-19 vaccines.

Net income in 2020 was $185.2 million, compared to $65.2 million in the prior year. Net income increased primarily due to increased sales.

Net income attributable to common shareholders was $104.4 million, or $1.06 per basic and $0.97 per diluted share, compared to net income attributable to common shareholders of $39.8 million, or $0.42 per basic and $0.41 per diluted share, in the prior year.

Excluding the implementation of the Rights Agreement, as described above, and the newly-issued common and preferred shares, basic and diluted earnings per share for 2020 would be $1.55 and $1.29, respectively.

Non-GAAP adjusted EBITDA was $229.9 million in 2020, compared to $76.4 million in the prior year. Non-GAAP net income in 2020 was $197.1 million in 2020, compared to $68.5 million in the prior year. Non-GAAP diluted earnings per share in 2020 was $1.03, compared to earnings of $0.43 per share in the prior year. Non-GAAP diluted earnings per share in 2020, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $1.45 per share. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement.

As of December 31, 2020, cash and cash equivalents totaled $1,041.0 million, compared to $152.7 million as of December 31, 2019. In 2020, net cash provided by operating activities was $479.3 million, net cash used in investing activities was $204.8 million, and net cash provided by financing activities was $592.6 million, including proceeds of $541.0 million from a subsidiary's financing, loan proceeds of $33.2 million, and loan repayments of $6.0 million. As of December 31, 2020, the Company had $32.9 in bank loans due within one year. The Company expects that its current cash position will be able to support its operations for at least the next 12 months.

Legal Proceedings

As previously disclosed by the Company, on March 13, 2018, 1Globe Capital LLC ("1Globe") filed a complaint against the Company in the Antigua Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his judgment (the "Antigua Judgment"), finding the Company fully in favor, dismissing 1Globe's claim and declaring that the Rights Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe's rights or shareholding or otherwise distributing the exchange shares to the Company's shareholders who did not trigger the Rights Plan until after the determination of the appeal (the "Exchange Shares"). 1Globe's appeal against the Antigua Judgment was heard on September 18, 2019, and the appeal decision is now pending.

As previously disclosed, on March 5, 2018, the Company filed a lawsuit in the Court of Chancery of the State of Delaware seeking a determination on whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC, and certain other shareholders of the Company had triggered the Rights Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company's complaint, counterclaims, and a third-party complaint against the Company and Mr. Weidong Yin alleging, among other allegations, that the Rights Agreement is not valid. On March 6, 2019, the Delaware Chancery Court entered a status quo order, providing that the Company not distribute any of the Exchange Shares to the Company's shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or further order of the Court. On April 8, 2019, the Delaware Chancery Court stated that the Delaware litigation was pending the outcome of 1Globe's appeal of the Antigua Judgment.

Separately, Heng Ren Investments LP ("Heng Ren") filed suits against Sinovac and Weidong Yin on May 31, 2019, in Massachusetts state court, for alleged breach of fiduciary duties and wrongful equity dilution. Sinovac moved the matter from the state court to the United States District Court for the District of Massachusetts. Heng Ren alleged that Mr. Yin breached fiduciary duties owed to minority shareholders, that Sinovac aided and abetted breaches of fiduciary duties, and that both Sinovac and Mr. Yin engaged in wrongful equity dilution. Heng Ren requested damages, attorney fees, and prejudgment interest. On September 14, 2020, Sinovac Antigua filed a motion to dismiss Heng Ren's claims. The court's decision on this motion is still pending.

Status of Exchange Shares and Trading in the Company's Shares

As a result of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company's shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgement and the final disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding. The Nasdaq Stock Market LLC implemented a halt on trading of the Company's common shares at the time the Exchange Shares were issued to the trust. The Company is currently unable to estimate when trading will resume, or whether Nasdaq will take any additional action in regards to the trading of the Company's common shares.

http://www.sinovac.com.cn/news/shownews.php?id=1207&lang=en

WuXiAppTec Co., Ltd. (SHA: 603259, HK: 2359)

Established in December 2000, WuXiAppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXiAppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXiAppTec's open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need - and to fulfill our dream that "every drug can be made and every disease can be treated."

https://www.wuxiapptec.com/about/overview

WuXiAppTec Reports Record First-Quarter In 2022

25/4/2022

Revenue Up 71.2% Year-Over-Year to RMB8,474 Million

Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million

Diluted Earnings Per Share (EPS) Up 3.9% Year-Over-Year to RMB0.53

Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 85.8% Year-Over-Year to RMB2,053 Million

Adjusted Non-IFRS Diluted EPS Up 81.6% Year-Over-Year to RMB0.69[2]

(SHANGHAI, April 25, 2022) - WuXiAppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first quarter ending March 31, 2022 ("Reporting Period").

This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the 2022 First-Quarter Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in dealing in the shares of the Company.

All financials disclosed in this press release are prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.

The 2022 First-Quarter Report of the Company has not been audited.

First-Quarter 2022 Financial Highlights

Revenue grew 71.2% year-over-year to RMB 8,474 million. This is primarily attributable to the Company's continued focus on leveraging its unique CRDMO business model to achieve synergy and strong growth across our business segments:

WuXi Chemistry revenue grew 102.1% to RMB 6,118 million and adjusted non-IFRS gross profit grew 89.8% to RMB 2,466 million, with a gross profit margin of 40.3%.

WuXi Testing revenue grew 31.7% to RMB1,279 million and adjusted non-IFRS gross profit grew 36.9% to RMB456 million, with a gross profit margin of 35.7%.

WuXi Biology revenue grew 26.2% to RMB533 million and adjusted non-IFRS gross profit grew 40.4% to RMB220 million, with a gross profit margin of 41.4%.

WuXi ATU revenue grew 37.0% to RMB299 million and adjusted non-IFRS gross profit declined to RMB-22 million, with a gross profit margin of -7.5%.

WuXi DDSU revenue declined 21.6% to RMB241 million and adjusted non-IFRS gross profit declined 45.1% to RMB80 million, with a gross profit margin of 33.1%.

IFRS gross profit increased 64.0% year-over-year to RMB3,015 million. Gross profit margin was 35.6%.[1]

Adjusted Non-IFRS gross profit increased 65.3% year-over-year to RMB3,202 million. Adjusted Non-IFRS gross margin was 37.8%.

EBITDA increased 16.8% year-over-year to RMB 2,441 million.

Adjusted EBITDA increased 67.5% year-over-year to RMB2,854 million.

Net profit attributable to owners of the Company increased 9.5% year-over-year to RMB1,643 million.

Adjusted non-IFRS net profit attributable to owners of the Company increased 85.8% year-over-year to RMB2,053 million.

Diluted EPS increased 3.9% year-over-year to RMB0.53, while adjusted diluted non-IFRS EPS increased by 81.6% year-over-year to RMB0.69.

First-Quarter 2022 Business Highlights

In the first quarter of 2022, demand for our services was strong and we grew our customer base to more than 5,800 active accounts by adding more than 320 new customers. We continued to optimize cross-platform synergies to better serve our customers worldwide, strengthen our unique competitive advantage as a fully integrated CRDMO (Contract Research Development and Manufacturing Organization) and CTDMO (Contract Testing Development and Manufacturing Organization), and provide one-stop services for our clients from discovery to development and manufacturing. Revenue growth was demonstrated across our expanding global customer base:

Revenue from US-based customers grew 84% to RMB5,278 million; revenue from Europe-based customers grew 83% to RMB1,217 million; revenue from China-based customers grew 37% to RMB1,587 million; and revenue from other regions grew 51% to RMB393 million.

We continued to expand our customer base and retain existing clients. During the Reporting Period, revenue from existing clients grew 75% to RMB8,322 million and new clients contributed RMB153 million in revenue.

During the Reporting Period, revenue from the top 20 global pharmaceutical companies grew 140%, up to RMB3,807 million in revenue; revenue generated from all other customers grew 39% to RMB4,668 million.

Our unique positioning across the pharmaceutical development value chain drove our "follow-the-customer" and "follow-the-molecule" strategies and enhanced synergies across our business segments. Customers using services from multiple business units contributed RMB7,392 million in revenue, growing 87% year-over-year.

WuXi Chemistry: CRDMO integrated business model drives revenue to double

Revenue grew 102.1% to RMB6,118 million and adjusted non-IFRS gross profit grew 89.8% to RMB2,466 million, with a gross margin of 40.3%. Excluding COVID-19 commercial projects, WuXi Chemistry revenue grew 52.3%.

Revenue from small molecule discovery services ("R") grew 46.6% to RMB1,745 million.

Our industry-leading small molecule drug discovery platform delivered more than 90,000 custom synthesized compounds to our clients in first quarter 2022. Through our small molecule discovery services, we enabled our customers to accelerate their research while generating opportunities for our downstream business units. As part of our "follow the customer" and "follow the molecule" strategies, we established trusted partnerships with our global customers, which helped sustain support for clinical and commercial projects and opportunities for the company. The small molecule discovery service provided a solid foundation to support the rapid and sustainable growth of our CRDMO business.

We continued executing our "long-tail" strategy, and those customers continue to have strong demands for our discovery services in small molecules, oligonucleotides and peptides.

Revenue from our small molecule development and manufacturing ("D&M") service grew 138.1% to RMB4,373 million.

During the Reporting Period, the Company added 217 new molecules to our 'D&M" pipeline funnel for a total of 1,808 molecules, including 42 in commercial stage, 49 in phase III, 271 in phase II and 1,446 in phase I and pre-clinical stages.

D&M service for new modalities is also gaining strong momentum. During the reporting period, the number of oligonucleotide and peptide D&M clients increased 72% to 86, and the number of oligonucleotide and peptide molecules increased 98% to 121. Revenue from oligonucleotide and peptide D&M reached RMB251 million.

Capacity expansion of WuXi Chemistry continued to accelerate in first quarter 2022. During the reporting period, we began to operate our facility in Changshu for drug substance manufacturing, and also began to operate part of Changzhou Phase 3 facility including a new R&D center and 2 plants.

WuXi Testing: strong growth in lab testing services

Revenue from WuXi Testing grew 31.7% to RMB1,279 million and adjusted non-IFRS gross profit grew 36.9% to RMB456 million, with a gross margin of 35.7%.

Revenue from lab testing services grew 39.9% year-over-year to RMB909 million.

The Company provides a full range of laboratory testing services to our customers, including DMPK (drug metabolism and pharmaco*kinetics), toxicology, and bioanalysis for drug development testing as well as medical device testing. We leveraged our integrated WuXiAppTec Investigational New Drug (IND) program (WIND) to generate preclinical data and prepare global regulatory submissions of IND packages, expediting the IND application process for many of our customers worldwide. Customers signed 47 WIND service packages with us in the first quarter of 2022.

Drug safety evaluation services achieved strong revenue growth of 53% year-over-year. We maintained our industry-leading position in Asia for drug safety evaluation services that meet global regulatory requirements.

Our largely US-based medical device testing business has turned around and grew 27% year over year.

Revenue from clinical CRO & SMO (site management organization) grew 15.2% year-over-year to RMB370 million.

For clinical CRO, the Company provided services to around 160 projects, enabling our customers to obtain 4 IND approvals.

For SMO, the Company continued its rapid expansion. Our SMO maintained more than 4,600 staff in around 150 cities in China, providing services in over 1,000 hospitals. The team size increased 26% year-over-year, demonstrating strong market demand for our SMO services. In the first quarter of 2022, SMO enabled 4 new drug approvals.

WuXi Biology: new modalities biology services drive growth

Revenue from WuXi Biology grew 26.2% to RMB533 million and adjusted non-IFRS gross profit grew 40.4% to RMB220 million, with a gross margin of 41.4%.

The Company has the largest discovery biology enabling platform, with more than 2,500 experienced scientists who provide comprehensive biology services covering all stages and therapeutic areas of drug discovery. The Company has established 3 centers of excellence for non-alcoholic steatohepatitis (NASH), anti-viral, neuroscience & aging.

The Company has a leading DNA Encoded Library (DEL) and compound generation platform. More than 1,100 customers globally now use our DEL services. We leverage our global network of sites in China, US and Germany to develop and use new technologies such as OBOC ("One-Bead-One-Compound") to drive growth and maintain business continuity.

The Company continues to build new biology capabilities related to new modalities, including target protein degradation, nucleic acid based and conjugated modalities, vector platform, and novel drug delivery vehicles. During the Reporting Period, revenue from new modalities and large molecules in WuXi Biology grew 110%, and its revenue contribution rose to 17.6% in the first quarter of 2022, from 14.6% in 2021, suggesting that new modalities-related biology services have become an increasingly important growth driver.

WuXi ATU: CTDMO business model drives growth

Revenue from WuXi ATU grew 37.0% to RMB299 million and adjusted non-IFRS gross profit declined to RMB-22 million, with a gross margin of -7.5%.

During the Reporting Period, the Company focused on improving our CTDMO integrated enabling platform and strengthened testing services, capabilities, and capacities. We provided development and manufacturing services for 74 projects, including 59 pre-clinical and Phase I projects, 7 Phase II projects, and 8 Phase III projects (4 projects are in BLA preparation stage).

The Company announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA[TM]) in March 2022. TESSA[TM] technology is a revolutionary and novel process for transfection-free, scalable manufacturing of adeno-associated virus (AAV), and the new data recently published in Nature Communications supports the benefits of this technology. It highlights that in the same manufacturing volume, TESSA[TM] vectors produced 10 times more AAV than plasmid-based technology. By end of first quarter 2022, we have 14 TESSA[TM] evaluation projects.

Gross profit declined in Q1-2022 largely due to under-utilized capacities of the newly built Shanghai Lin-gang site and the new testing facility in Philadelphia. With capacity utilization ramping up in the coming quarters, gross profit is expected to turn positive and increase.

WuXi DDSU: business evolving to focus more on innovative drug discovery

Revenue from WuXi DDSU declined 21.6% to RMB241 million and adjusted non-IFRS gross profit declined 45.1% to RMB80 million, with a gross margin of 33.1%. DDSU's revenue decline was mainly attributed to business adjustments that aim to better serve the growing needs of clients in China for novel and differentiated products that will take longer to deliver INDs.

During the Reporting Period, our success-based drug discovery service unit filed INDs for 2 drug candidates and obtained 16 CTAs on behalf of China-based customers. As of March 31, 2022, we have cumulatively submitted 146 new chemical entity IND filings with the NMPA and obtained 126 CTAs, with 1 project in NDA review stage, 3 projects in Phase III clinical trials, 16 projects in Phase II clinical trials, and 74 projects in Phase I clinical trials. Upon these products' successful launch to the market by our customers, we will begin receiving royalty income.

Among the 146 projects for which INDs were filed or are currently in clinical stage, about 70% of them rank in the top three in China in terms of drug development progress among same-class drug candidates.

Continuous Improvements in ESG Management and Performance

As an enabler of innovation, a trusted partner, and a contributor to the global healthcare community, WuXiAppTec is deeply committed to sustainability and actively practices global corporate citizenship.

In the first quarter of 2022, WuXiAppTec was recognized as a "Top Rated" ESG company by Sustainalytics, a leading ESG research, ratings and data firm. In the same assessment, WuXiAppTec was placed in the top 4 percent of companies in the global pharmaceutical industry with a "Low Risk" of experiencing material financial impacts from ESG factors.

Looking forward, we remain committed to "doing the right thing and doing it right." We will continue to focus on delivering on our ESG commitments and ensuring that sustainability remains a priority across our business operations today and in the future.

Management Comment

Dr. Ge Li, Chairman and CEO of WuXiAppTec, said, "We achieved record growth in the first quarter of 2022. Our revenue increased 71.2% YoY and our adjusted Non-IFRS net profit increased 85.8% YoY. WuXiAppTec's performance during the first quarter of 2022 underscores that our unique CRDMO and CTDMO business models continue to drive the rapid growth for our company and allow us to better enable customers worldwide."

"After the outbreak of Omicron in Shanghai at the end of the first quarter, we quickly implemented our business continuity plan to ensure the health of our employees whilst operating our business continuously. We effectively leveraged our global capacities and comprehensive capabilities to meet project delivery timelines and capture new business opportunities. If the Omicron outbreak in Shanghai can be largely contained by April, we expect 63-65% YoY revenue growth for the second quarter and 65-70% revenue growth for the full year of 2022. Our management team will closely monitor the development of the outbreak and will provide business updates when appropriate."

https://www.wuxiapptec.com/news/wuxi-news/5039

Xian Janssen Pharmaceutical Ltd. (NYSE: JNJ)

Xian Janssen Pharmaceutical Ltd. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. It is one of China's largest pharmaceutical companies and among the earliest multinational pharmaceutical companies to enter China simultaneous with the opening up of China's economy.

Since its establishment in 1985, Xian Janssen has been committed to providing Chinese patients with high-quality, innovative products that fulfill unmet medical needs in psychiatry, neurology, oncology, immunology, and gastrointestinal, fungal and infectious diseases.

Based on the company's Credo and spirit of caring, Xian Janssen has been an active corporate citizen, successfully implementing more than 50 cooperative projects in the areas of medicine, public health, medical R&D, and corporate social responsibility.

http://www.xian-janssen.com.cn/en/about-xian-janssen/company-overview

Johnson & Johnson Reports 2019 Third-Quarter Results.

23/10/2019

For the full release see:

https://johnsonandjohnson.gcs-web.com/static-files/3671f909-a0e9-41c1-b067-290dd786bfe5

ACQ_REF: IS/42727/20240402/CHN/24/11

ACQ_AUTHOR: Associate/Audrey Anak Awie

COPYRIGHT 2024 Acquisdata, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.

LATEST COMPANY NEWS. - Free Online Library (2024)

References